GDTC · CytoMed Therapeutics Limited

CytoMed Therapeutics Limited announced its full-year 2025 financial results, revealing a GAAP net loss of US$3.11 million, up from US$1.96 million in 2024, primarily due to elevated research expenses of US$1.72 million (versus US$1.48 million prior year) from higher consumables, employee benefits, and clinical trial costs—partially offset by lower depreciation and professional fees—and other expenses of US$1.30 million, driven by investor relations and non-cash share-based payments. Employee benefits rose to US$723,667, including US$240,491 in share-based compensation, the first such awards post-IPO. Adjusted for non-cash share-based payments (US$539,855) and public listing costs (US$452,092), the loss would have been US$2.12 million. Revenue and other operating income grew modestly to US$780,857 from US$663,786. Balance sheet shows cash at US$1.63 million, down from US$3.87 million, with borrowings of US$318,456 funding five properties in Singapore and Malaysia. Clinically, the ANGELICA CAR-T Phase I trial at National University Hospital Singapore has dosed six patients at levels 1-2, advancing to level 3 with completion targeted for 2026. A new MOU with Universiti Malaya supports a Phase I trial for unmodified γδ T cells (CTM-GDT) in no-option cancer patients, with IND submission before June 2026. A preclinical study co-authored with MD Anderson highlights CTM-GDT potential for AML. Corporately, via subsidiary LongevityBank, acquired Malaysian cord blood bank assets including a private license for stem cell banking and NK cell therapies, plus equity in a medical clinic. Management expresses caution for 2026 amid global volatility but affirms sufficient resources from low-cost infrastructure and research product sales, while pursuing strategic partnerships.